A Prospective, Multi-Center, Randomized, Double-Masked, Positive Controlled, Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate Ophthalmic Suspension (1%) in Patients With Non-Infectious Anterior Segment Uveitis

Trial Profile

A Prospective, Multi-Center, Randomized, Double-Masked, Positive Controlled, Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate Ophthalmic Suspension (1%) in Patients With Non-Infectious Anterior Segment Uveitis

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2018

At a glance

  • Drugs Dexamethasone (Primary) ; Prednisolone acetate
  • Indications Anterior uveitis
  • Focus Registrational; Therapeutic Use
  • Sponsors EyeGate Pharma
  • Most Recent Events

    • 24 Jul 2018 Status changed from active, no longer recruiting to completed.
    • 17 May 2018 Planned End Date changed from 1 Nov 2018 to 8 Jun 2018.
    • 06 Apr 2018 Data from this trial will be used to support a New Drug Application (NDA) to the US FDA for EGP-437 which is expected in the first half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top